Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic

Summary
The purpose of this Health Alert Network (HAN) Advisory is to alert public health departments, healthcare professionals, first responders, harm reduction organizations, laboratories, and medical examiners and coroners to—

1. substantial increases in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids excluding methadone (hereafter referred to as synthetic opioids), likely illicitly manufactured fentanyl;

2. a concerning acceleration of the increase in drug overdose deaths, with the largest increase recorded from March 2020 to May 2020, coinciding with the implementation of widespread mitigation measures for the COVID-19 pandemic;

3. the changing geographic distribution of overdose deaths involving synthetic opioids, with the largest percentage increases occurring in states in the western United States;

4. significant increases in overdose deaths involving psychostimulants with abuse potential (hereafter referred to as psychostimulants) such as methamphetamine; and

5. recommendations for communities when responding to the evolving overdose crisis.

Background
The most recent provisional data available from the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS) indicate that approximately 81,230 drug overdose deaths occurred in the United States in the 12-months ending in May 2020 (Figure 1). This represents a worsening of the drug overdose epidemic in the United States and is the largest number of drug overdoses for a 12-month period ever recorded. After declining 4.1% from 2017 to 2018, the number of overdose deaths increased 18.2% from the 12-months ending in June 2019 to the 12-months ending in May 2020 (Figure 1). Drug overdose deaths during this time increased more than 20% in 25 states and the District of Columbia, 10% to 19% in 11 states and New York City, and 0% to 9% in 10 states. Drug overdose deaths decreased in four states (Figure 2).

The recent increase in drug overdose mortality began in 2019 and continues into 2020, prior to the declaration of the COVID-19 National Emergency in the United States in March. The increases in drug overdose deaths appear to have accelerated during the COVID-19 pandemic. Provisional overdose death estimates indicate that the largest monthly increases in drug overdose deaths occurred in the 12-months ending in February 2020 (74,185 deaths) and the 12-months ending in March 2020 (75,696 deaths), the 12-months ending in March 2020 (75,696 deaths) to the 12-months ending in April 2020 (77,842 deaths), and from the 12-months ending in April 2020 (77,842 deaths) to the 12-months ending in May 2020 (81,230 deaths). These one-month increases of
2,146 deaths and 3,388 deaths, respectively for the 12-month periods (Figure 1), are the largest monthly increases documented since provisional 12-month estimates began to be calculated in January 2015.\(^3\)

Synthetic opioids are the primary driver of the increases in overdose deaths. The 12-month count of synthetic opioid deaths increased 38.4% from the 12-months ending in June 2019 compared with the 12-months ending in May 2020 (Figure 1). Of the 38 jurisdictions with available synthetic opioid data,\(^3\) 37 jurisdictions reported increases in synthetic opioid overdose deaths for this time period. Eighteen of these jurisdictions reported increases greater than 50%, 11 reported increases of 25% to 49%, 7 reported increases of 10% to 24%, 1 reported an increase <10% (See Figure 3). State and local health department reports indicate that the increase in synthetic opioid-involved overdoses is primarily linked to illicitly manufactured fentanyl.\(^4,5\) Historically, deaths involving illicitly manufactured fentanyl have been concentrated in the 28 states east of the Mississippi River, where the heroin market has primarily been dominated by white powder heroin.\(^5,7\) In contrast, the largest increases in synthetic opioid deaths from the 12-months ending in June 2019 to the 12-months ending in May 2020 occurred in 10 western states (98.0% increase).\(^{[iii]}\) This is consistent with large increases in illicitly manufactured fentanyl availability in western states\(^5\) and increases in fentanyl positivity in clinical toxicology drugs tests in the West after the COVID-19 pandemic.\(^9\) Increases in synthetic opioid overdose deaths were also substantial in other regions: 12 southern states and the District of Columbia (35.4%), 6 midwestern states (32.1%), and 8 northeastern states and New York City (21.1%) (Figure 3).

Overdose deaths involving cocaine also increased by 26.5% from the 12-months ending in June 2019 to the 12-months ending in May 2020 (Figure 1). Other data have shown that recent increases in overdose deaths involving cocaine are primarily related to overdose deaths that involved both cocaine and synthetic opioids (primarily illicitly manufactured fentanyl).\(^10\) These deaths are likely linked to co-use of cocaine among people injecting opioids such as illicitly manufactured fentanyl or heroin.\(^11\) In contrast, overdose deaths involving psychostimulants, such as methamphetamine, have been increasing with and without synthetic opioid co-use and at a rate faster than overdose deaths involving cocaine.\(^10\) Provisional 12-month counts of overdose deaths involving psychostimulants in the United States increased by 34.8% from the 12-months ending in June 2019 compared to the 12-months ending in May 2020. The number of deaths involving psychostimulants now exceeds the number of cocaine-involved deaths (Figure 1). These increases are consistent with the increased availability of methamphetamine in the illicit drug supply and increases in methamphetamine-related treatment admissions.\(^8,12-14\)

**Recommendations**

These newly released provisional fatal overdose data, coupled with the known disruption to public health, healthcare, and social services as a result of the COVID-19 pandemic and related mitigation measures, highlight the need for essential services to remain accessible for those most at risk of overdose and the need to expand prevention and response activities. CDC recommends the following actions as appropriate based on community needs and characteristics:

1) **Expand the provision and use of naloxone and overdose prevention education**

   o **Public health departments and community-based organizations:**
     - Raise awareness about
       1) The critical need for bystanders to have naloxone on hand and use it during an overdose;
       2) The changing illicit drug marketplace and the wider availability and geographic dispersion of illicitly manufactured fentanyl and novel psychoactive substances (e.g., fentanyl analogs);
       3) Common co-use of illicitly manufactured fentanyl with other drugs such as cocaine and methamphetamine; and
       4) Infrequent mixing of illicitly manufactured fentanyl into the illicit drug supplies of methamphetamine and cocaine.\(^7,12\)
     - Increase awareness about the risk of using drugs when alone and emphasize the need for risk reduction strategies among people who use drugs, including during the COVID-19 pandemic. **Strategies can include**
       o Not using drugs alone and knowing what drugs are being used;
       o Ensuring naloxone is available and that people who use drugs and their loved ones know how to administer it; and
       o Having a friend or loved one check in on people who use drugs regularly, especially during use.
- Provide messaging to community groups (particularly those providing services to high risk populations), community leaders, school officials, faith based leaders, parents, students and others about the changing illicit drug supply and risks for overdose and exposure to highly potent opioids such as illicitly manufactured fentanyl or counterfeit drugs appearing to be legal prescription medications.

  o Healthcare providers:
    - Talk to patients about the changing illicit drug supply and risks for overdose and exposure to highly potent opioids such as illicitly manufactured fentanyl.
    - **Prescribe naloxone** to individuals at risk for opioid overdose, such as those with a prior history of overdose, those with opioid use disorder, and individuals using illicit opioids and other drugs that might be mixed with illicitly manufactured fentanyl.
    - Co-prescribe naloxone to patients with high morphine milligram equivalents and those receiving opioids and benzodiazepines.¹⁵
    - Expand locations in which overdose prevention education and take-home naloxone are provided. These locations can include inpatient and outpatient treatment programs, primary care settings, retail pharmacies, counseling and support groups, and other community-based settings. Expanding locations may be especially important in rural areas.¹⁶-¹⁸
    - Counsel patients that multiple doses of naloxone may be needed for a single overdose event because of the potency of illicitly manufactured fentanyl and fentanyl analogs,¹⁹ and that multiple doses of naloxone may be needed over time due to prolonged effects of opioids in some cases.⁵,²⁰

  o Harm reduction organizations:
    - Increase the provision of overdose prevention education and take-home naloxone to people who use drugs, their friends, and others likely to witness or experience an overdose.⁷,²¹-²³
    - Ensure that individuals have sufficient doses of take-home naloxone to account for the potency of illicitly manufactured fentanyl and fentanyl analogs.²⁴
    - Call 911 immediately after recognizing an overdose or resuscitating a patient. Naloxone available in the field may not be sufficient to reverse the overdose. Those who receive naloxone may experience a recurrence of overdose symptoms or experience other acute medical, traumatic, toxicologic, or psychiatric conditions.²⁵,²⁶
    - Prioritize naloxone distribution to people who use drugs following periods of abstinence and during transitions where opioid tolerance may have waned. There is a higher risk of overdose during these periods, including post-incarceration and after treatment for an opioid use disorder, if a relapse occurs.²⁷,²⁸

  o First responders to overdoses:
    - Increase the amount of naloxone on hand given the increased amount needed and rate of use for overdoses involving illicitly manufactured fentanyl and fentanyl analogs.²⁹
    - **Implement and improve post-overdose outreach and follow-up** via peer recovery support specialists to promote engagement in treatment.
    - **Take steps to reduce the risk of COVID-19 exposure when responding to a suspected drug overdose and administering naloxone.** These steps include using personal protective equipment (PPE) and positioning the person's head facing away from you when administering naloxone.

2) Expand access to and provision of treatment for substance use disorders

  o Healthcare providers:
    - **Provide Medications for Opioid Use Disorder (MOUD)**
      - Treatment with the FDA-approved medications methadone, buprenorphine, or naltrexone are lifesaving and the **most effective forms of treatment for opioid use disorder**.
      - Ensure treatment access, especially for people who are transitioning from institutional settings such as the criminal justice system, residential treatment, or a recent hospitalization.⁷,³⁰
      - During the COVID-19 public health emergency, the Federal Government has made it easier to obtain MOUD through telehealth.³¹-³³
        - Find [treatment options](#) or call 1-800-662-HELP (4357).
- SAMHSA’s [Buprenorphine Practitioner Locator](https://buprenorphinepractitionerlocator.samhsa.gov) can help identify a qualified practitioner who can prescribe buprenorphine.

**Provide Stimulant (Cocaine, Methamphetamine) Use Disorder Treatment**
- Unlike opioid use disorder treatment, there are no FDA-approved medications to treat stimulant use disorders.
- The most effective treatments for stimulant use disorders are psychosocial therapies such as motivational interviewing, contingency management, contingency management combined with community reinforcement approach, and contingency management combined with cognitive-behavioral therapy. These therapies have demonstrated effectiveness for stimulant use disorders. For additional information about each of these treatment strategies, see [SAMHSA’s Treatment for Stimulant Use Disorders](https://www.samhsa.gov/treatment-for-stimulant-use-disorders).

- **Find treatment options** or call 1-800-662-HELP (4357).

- **Harm reduction organizations:**
  - Offer buprenorphine on-site, in a mobile van, or through telemedicine for clients with opioid use disorder.34-36

3) **Intervene early with individuals at the highest risk for overdose**
- **Public health departments and harm reduction organizations:**
  - Link people who are at risk for overdose with care and track their retention in care programs. People who are at risk include those who have recently been treated for a non-fatal overdose.37,38
  - Consider expanding peer navigator programs or using recovery coaches to intervene with individuals at the highest risk of overdose.39

- **Healthcare providers:**
  - Initiate or continue medications for opioid use disorder among people leaving correctional and detention facilities. See Recommendation #2 on treatment.
  - Provide active referral-to-treatment options and recovery support services.40
  - Implement post-overdose response protocols, including in emergency departments, that incorporate links between public health, treatment providers, community-based service organizations, and healthcare providers. These protocols promote overdose education, treatment, linkage to care and MOUD, and naloxone distribution.41,42

- **Public safety:**
  - Divert individuals with low-level drug offenses pending prosecution to case management and supportive wrap-around services instead of jail or prison and prosecution. Diversion enables long-term treatment and recovery.43,44 Examples of diversion programs include [Police Assisted Addiction and Recovery Initiative (PAARI)](https://www.policeassistedaddiction.org) and [Law Enforcement Assisted Diversion (LEAD)](https://www.leadusa.org).

4) **Improve detection of overdose outbreaks due to fentanyl, novel psychoactive substances (e.g., fentanyl analogs), or other drugs to facilitate an effective response**
- **Public health departments:**
  - Identify drug overdose outbreaks and spikes rapidly using existing surveillance systems such as syndromic surveillance emergency department data, emergency medical services data, commercial laboratory data, poison center data, medical examiner or coroner data, and tools like Overdose Detection – Mapping Application Program (ODMAP). Existing syndromic surveillance emergency department data sources include CDC’s Drug Overdose Surveillance and Epidemiology (DOSE) system and the National Syndromic Surveillance Program (NSSP).7,9,45,46
  - Track and monitor trends in the illicit opioid drug supply and overdoses, using local, state, and federal data systems and toxicological testing, including:
    - The geographic distribution of illicit drugs and overdoses;
    - Shifts in demographic characteristics of individuals at risk for overdose (e.g., by sex, race/ethnicity); and
    - The identification of the drugs with which opioids are mixed and drug products containing multiple opioids (e.g., heroin and illicitly manufactured fentanyl).

- **Medical examiners and coroners:**
- **Screen specimens**, including in suspected overdose deaths involving heroin, using an enzyme-linked immunosorbent assay (ELISA) test that can detect substances including fentanyl and fentanyl analogs. See laboratory section below.
- Screen for novel psychoactive substances prevalent in your region or when an unexplained increase in drug overdoses occurs.
  - Consider specialized testing for fentanyl analogs or other novel synthetic opioids when fentanyl screening is negative, or confirmatory testing is inconclusive, yet opioid or fentanyl overdose is highly suspected. This is particularly important if an increase in overdoses is occurring or fentanyl analogs have been detected in local drug products.

*Laboratories:*
- Implement an opioid biosurveillance program in line with the Association of Public Health Laboratories (APHL) guidance on developing model surveillance systems for use in tracking non-fatal opioid overdoses at the state level.
- Use CDC’s Traceable Opioid Material® Kits (TOM Kits®). This product line provides reference materials enabling labs to screen for more than 210 synthetic opioid compounds – including more than 190 fentanyl analogs. Available kits include the Opioid Certified Reference Material kit (Opioid CRM kit) and the Fentanyl Analog Screening (FAS) Kit.

*Harm reduction organizations:*
- Implement drug checking services and drug supply surveillance in line with applicable state and local laws.
- Partner with public safety and public health to obtain and disseminate the latest information on local drug supply and overdose trends.
Figure 1: Twelve-month provisional\textsuperscript{a} drug overdose death counts for all drugs\textsuperscript{b}, synthetic opioids\textsuperscript{c}, cocaine\textsuperscript{d}, and psychostimulants\textsuperscript{e}, for 50 states, the District of Columbia, and New York City: 12-months ending in June 2019 to 12-months ending in May 2020\textsuperscript{f}

\textsuperscript{a} Provisional drug overdose death counts are based on death records received and processed by NCHS. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Provisional data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete reporting.

\textsuperscript{b} Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14. The drug classes are all nested within all drug overdose deaths, but multiple drug classes may be involved in a single drug overdose death.

\textsuperscript{c} Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).

\textsuperscript{d} Drug overdose deaths, as defined, that involve cocaine (T40.5).

\textsuperscript{e} Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).

\textsuperscript{f} Included time periods will have some amount of overlap. For example, the 12-months ending in June 2019 (i.e., July 2018 to June 2019) includes deaths occurring in June 2019, which is also included separately in 12-months ending in May 2020 (i.e., June 2019 to May 2020).
Figure 2: Percentage change in 12-months ending provisional\(^a\) data on all fatal drug overdoses\(^b\), 50 states, the District of Columbia, and New York City: Overdose deaths from 12-months ending in June 2019 to 12-months ending in May 2020\(^c\)

\(^a\) Provisional drug overdose death counts are based on death records received and processed by NCHS. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Provisional data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete reporting.

\(^b\) Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified using underlying cause-of-death codes X40–X44, X80–X84, X65, and Y10–Y14.

\(^c\) Included time periods will have some amount of overlap. For example, the 12-months ending in June 2019 (i.e., July 2018 to June 2019) includes deaths occurring in June 2019, which is also included separately in 12-months ending in May 2020 (i.e., June 2019 to May 2020).
Figure 3: Percentage change in 12-months ending provisional\(^a\) count of fatal overdoses involving synthetic opioids\(^b\), 36 states, the District of Columbia, and New York City\(^c\): Deaths from 12-months ending in June 2019 to 12-months ending in May 2020\(^d\)

---

\(^a\) Provisional drug overdose death counts are based on death records received and processed by NCHS. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Provisional data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete reporting.

\(^b\) Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).

\(^c\) Jurisdictions with fewer than 20 predicted overdose deaths involving synthetic opioids were excluded, as well as those with suppressed data due to data quality issues.

\(^d\) Included time periods will have some amount of overlap. For example, the 12-months ending in June 2019 (i.e., July 2018 to June 2019) includes deaths occurring in June 2019, which is also included separately in 12-months ending in May 2020 (i.e., June 2019 to May 2020).

**For Missouri partners and stakeholders:**

Inquires related to harm reduction, risk reduction, overdose and safe drug use should be referred to the following:

- **Primary:** Neann Wedgeworth, Harm Reduction Coordinator
  - E-mail: neann.wedgeworth@health.mo.gov
  - Telephone: (573)751-6131
- **Secondary:** Tara McKinney, Viral Hepatitis Prevention Coordinator
  - E-mail: tara.mckinney@health.mo.gov
  - Telephone: (573) 751-6360

Inquires related to overdose data should be referred to the following:

- **Primary:** Lynn Smith, Opioid Overdose Prevention Program Manager
- E-mail: Lynn.Smith@health.mo.gov
- Telephone: (573) 526-4862

**Media Inquiries:**
- Primary: Lisa Cox
  - E-mail: Lisa.Cox@health.mo.gov

**DHSS Resources:**
- Missouri Opioids Information: [https://health.mo.gov/data/opioids/](https://health.mo.gov/data/opioids/)
- Missouri Opioid Overdose and Bloodborne Infection Vulnerability Assessments: [https://health.mo.gov/data/opioids/assessments.php](https://health.mo.gov/data/opioids/assessments.php)

**Department of Mental Health (DMH)**

Inquires related to *substance use and substance use treatment* should be referred to the following:
- Primary: Andrea Kimball
  - E-mail: andrea.kimball@dmh.mo.gov
- Secondary: Christine Smith
  - E-mail: christine.smith@dmh.mo.gov

**Media Inquiries:**
- Primary: Debra Walker
  - E-mail: debra.walker@dmh.mo.gov
  - Telephone: (573) 751-1647

**DMH Resources:**
- Alcohol and Drug Use: [https://dmh.mo.gov/alcohol-drug](https://dmh.mo.gov/alcohol-drug)

**Other Resources:**
- CDC Health Alert Network: [https://emergency.cdc.gov/han/](https://emergency.cdc.gov/han/)
- Time 2Act: [https://time2actmissouri.com/resource-links](https://time2actmissouri.com/resource-links)
- NOMODEATHS: [https://www.nomodeaths.org/](https://www.nomodeaths.org/)
For More Information

- CDC Opioid Overdose homepage: "Understanding the Epidemic"
- CDC Health Advisory: Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities
- CDC Health Advisory: Influx of Fentanyl-laced Counterfeit Pills and Toxic Fentanyl-related Compounds Further Increases Risk of Fentanyl-related Overdose and Fatalities
- CDC Health Advisory: Rising Numbers of Deaths Involving Fentanyl and Fentanyl Analogs, Including Carfentanil, and Increased Usage and Mixing with Non-opioids

References


32. Drug Enforcement Administration. Flexibility during the nationwide public health emergency to prescribe buprenorphine.

33. Substance Abuse and Mental Health Services Administration (SAMHSA): Opioid Treatment Program (OTP) Guidance.


The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

Categories of Health Alert Network messages:

Health Alert Requires immediate action or attention; highest level of importance
Health Advisory May not require immediate action; provides important information for a specific incident or situation
Health Update Unlikely to require immediate action; provides updated information regarding an incident or situation
HAN Info Service Does not require immediate action; provides general public health information

---

This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, HAN coordinators, and clinician organizations.